Albany Urologic Oncology specializes in the screening, detection, treatment and consultation for disorders and cancers of the male genital-urinary system and the female urinary system.
Both Dr. Michael Perrotti and Dr. Efrossini Kolios are welcoming new patients at this time. Please call the office at 518-438-5300 to make an appointment.
We are conveniently located on the St. Peter's Hospital Mercy Care Campus. Our office hours are 8 a.m. to 4 p.m. Monday through Friday.
UroNav MRI Fusion Prostate Biopsy
Albany Urologic Oncology is now offering UroNav Fusion Biopsy. The UroNav Fusion Biopsy System from Invivo fuses pre-biopsy MR images of the prostate with ultrasound-guided biopsy images in real time. This provides excellent delineation of the prostate and suspicious lesions, as well as clear visualization of the biopsy needle. UroNav brings the power of MRI to the Urology suite for target identification of suspicious prostate lesions. Learn more by reading the articles below:
- Read research article, "MRI Detection of Prostate Cancer with the UroNav MRI Fusion Platform," by Dr. Perrotti.
- Read research article, "Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostate biopsy: a pilot study," by Dr. Perrotti.
- Read research article, "Understanding PSA and Prostate Cancer Risk Assessment," by Dr. Perrotti.
Albany Urologic Oncology is also offering 4KScore Test for Prostate Cancer Risk Assessment.
What is the 4KScore Test for Prostate Cancer Risk Assessment?
The 4KScore starts with a simple blood draw. The blood test combines four prostate-specific biomarkers with clinical information to provide men with an accurate and personalized assessment of their risk for aggressive prostate cancer. The 4KScore can be used in men with elevated serum PSA level and may help decide whether prostate biopsy is necessary. The 4KScore may be performed prior to initial prostate biopsy, or after a negative prostate biopsy when there is still concern for prostate cancer due to an elevated serum PSA level.